share_log

6-K: Financial Report for the Period 1 January 2024 to 30 June 2024

6-K: Financial Report for the Period 1 January 2024 to 30 June 2024

6-K: 2024年1月1日至2024年6月30日期間的財務報告
美股SEC公告 ·  08/07 18:56
牛牛AI助理已提取核心訊息
Novo Nordisk A/S, a global healthcare leader in diabetes care, reported a significant increase in sales and operating profit for the first half of 2024. Sales rose by 24% in Danish kroner and 25% at constant exchange rates (CER) to DKK 133.4 billion, while operating profit grew by 18% in Danish kroner and 19% at CER to DKK 57.8 billion. The company's performance was particularly strong in North America, with a 36% increase in sales. Diabetes and Obesity care sales surged by 26% in Danish kroner, driven by GLP-1 diabetes sales growth and Obesity care growing by 37% in Danish kroner. However, rare disease sales saw a decrease. Novo Nordisk also completed the phase 3 FRONTIER 2 trial with Mim8 for haemophilia A and received a positive CHMP opinion for Wegovy in the EU. The company updated its 2024 outlook, expecting sales growth of 22-28% at CER and operating profit growth of 20-28% at CER. The financial report was released on August 7, 2024, alongside an earnings call for investors.
Novo Nordisk A/S, a global healthcare leader in diabetes care, reported a significant increase in sales and operating profit for the first half of 2024. Sales rose by 24% in Danish kroner and 25% at constant exchange rates (CER) to DKK 133.4 billion, while operating profit grew by 18% in Danish kroner and 19% at CER to DKK 57.8 billion. The company's performance was particularly strong in North America, with a 36% increase in sales. Diabetes and Obesity care sales surged by 26% in Danish kroner, driven by GLP-1 diabetes sales growth and Obesity care growing by 37% in Danish kroner. However, rare disease sales saw a decrease. Novo Nordisk also completed the phase 3 FRONTIER 2 trial with Mim8 for haemophilia A and received a positive CHMP opinion for Wegovy in the EU. The company updated its 2024 outlook, expecting sales growth of 22-28% at CER and operating profit growth of 20-28% at CER. The financial report was released on August 7, 2024, alongside an earnings call for investors.
全球醫療保健領袖——諾和諾德報告稱，2024年上半年銷售額和營業利潤顯著增長。銷售額以丹麥克朗計，呈增長趨勢，達到1334億克朗；以不變匯率計，增長幅度爲25%。營業利潤以丹麥克朗計，呈增長趨勢，達到578億克朗；以不變匯率計，增長幅度爲19%。公司在北美市場的表現尤爲強勁，銷售額增長達36%。糖尿病和肥胖症治療銷售額呈增長趨勢，以丹麥克朗計，增長幅度達到26%，GLP-1糖尿病治療銷售額增長，肥胖症治療銷售額以丹麥克朗計增長37%。然而，罕見病銷售額下降。諾和諾德還完成了Mim8用於血友病A的第三期FRONTIER 2試驗，並獲得歐洲藥品管理局關於Wegovy的積極意見。公司更新了2024年的展望，預計以不變匯率計銷售額增長22％至28％，營業利潤增長20％至28％。該業績於2024年8月7日發佈，與針對投資者的業績會同時召開。
全球醫療保健領袖——諾和諾德報告稱，2024年上半年銷售額和營業利潤顯著增長。銷售額以丹麥克朗計，呈增長趨勢，達到1334億克朗；以不變匯率計，增長幅度爲25%。營業利潤以丹麥克朗計，呈增長趨勢，達到578億克朗；以不變匯率計，增長幅度爲19%。公司在北美市場的表現尤爲強勁，銷售額增長達36%。糖尿病和肥胖症治療銷售額呈增長趨勢，以丹麥克朗計，增長幅度達到26%，GLP-1糖尿病治療銷售額增長，肥胖症治療銷售額以丹麥克朗計增長37%。然而，罕見病銷售額下降。諾和諾德還完成了Mim8用於血友病A的第三期FRONTIER 2試驗，並獲得歐洲藥品管理局關於Wegovy的積極意見。公司更新了2024年的展望，預計以不變匯率計銷售額增長22％至28％，營業利潤增長20％至28％。該業績於2024年8月7日發佈，與針對投資者的業績會同時召開。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。